Fundraising Fox
Menten AI
YC W20San Francisco, US · Founded 2020 · 2 employees · 15 known investors
Find your way into Menten AI
Sign up to see every warm intro you have to Menten AI
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Menten AI team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Menten AI develops generative AI software to design cyclic peptide therapeutics for drug targets beyond the reach of conventional small molecules and biologics. The company partners with major pharmaceutical firms to accelerate preclinical drug discovery.
Also known as Menten AI Holdings, Inc. · Inc. · Menten Biotechnology Labs · Menten Biotechnology Labs, Inc. · Menten AI
Founders & leadership· Y Combinator alumni (W20)
Menten AI was founded in 2020 by Tamas Gorbe and Hans Melo.
Investors · 15
How we know: the company's own site · the Y Combinator directory · open dataset · 5k.vc investor directory · Not right? Tell us
How we know: the company's own site · Y Combinator's founder network · Not right? Tell us
How we know: the company's own site · Y Combinator's founder network · Not right? Tell us
How we know: Alumni Ventures's portfolio page · Not right? Tell us
How we know: Basecamp Fund's portfolio page · Not right? Tell us
How we know: Feld Ventures's portfolio page · Not right? Tell us
__Twitter.png)
How we know: Y Combinator's founder network · Not right? Tell us
How we know: Y Combinator's founder network · Not right? Tell us
How we know: Y Combinator's founder network · Not right? Tell us
How we know: Y Combinator's founder network · Not right? Tell us
How we know: Y Combinator's founder network · Not right? Tell us
How we know: the VCSheet dataset · Y Combinator's founder network · Not right? Tell us
Funding
SEC filings, press & company announcements- Undisclosed amountSeed RoundJul 2020Source ↗
Source: company announcements and press reports — follow each round's link for the claim.
Company profile
researched Aug 2026Menten AI is a drug discovery company focused on the computational design of peptide macrocycles as therapeutics. Its stated aim is to make peptide macrocycles usable as medicines for complex biological targets, including protein-protein interfaces that are difficult to address with conventional approaches.
The company's platform, MAUD 1.0, designs peptide macrocycles de novo rather than relying on traditional screening libraries. Menten AI states the platform has been validated across the preclinical discovery pipeline and has produced designs exhibiting nanomolar-level potency, oral bioavailability, cell permeability, and a hit rate above 90%.
Business model
Menten AI works through partnerships, inviting pharmaceutical and biotech organizations to "partner with us" for peptide macrocycle design programs; the company states it is trusted by top-10 pharma partners.
▸Full profile — market position, technology, go-to-market
Market position
The company positions MAUD 1.0 as an alternative to traditional screening for peptide macrocycle discovery, and states it is backed by leading venture capital investors and used by top-10 pharma partners.
Menten AI differentiates its approach by combining generative AI with physics-based modeling and quantum simulations for de novo design of peptide macrocycles, contrasted with traditional library screening, and by targeting challenging protein-protein interfaces.
Technology
MAUD 1.0 is described as a physics-based generative platform for peptide macrocycle design, combining generative AI with physics-based models and quantum simulations to design and optimize drug-like peptides, with the goal of expanding accessible chemical space relative to traditional screening methods. Reported platform outputs include nanomolar-level potency, oral bioavailability, cell permeability, and a greater-than-90% hit rate across preclinical discovery.
Go-to-market
Pharmaceutical companies, including top-10 pharma partners, seeking peptide macrocycle candidates for complex drug targets such as protein-protein interfaces.", "go_to_market">
Compiled by commissioned research from 1 cited public sources — announcements, filings, and press listed under research sources below.
Key figures
latest reportedCompany-reported or press-reported figures, each dated to when it was claimed — not independently audited.
Founder mafia
2 people who came through Menten AI went on to found or lead other companies.
Related companies · 5
Companies working in the same space as Menten AI.
Legal entities · 1
corporate structure▸Research sources · 1
primary sources listed
- Menten AImenten.ai · web
1 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does Menten AI do?
- Menten AI applies physics-based generative AI to design de novo peptide macrocycles for drug discovery.
- Who founded Menten AI?
- Menten AI was founded by Tamas Gorbe, Hans Melo in 2020.
- Who are Menten AI's investors?
- Menten AI's investors include Y Combinator, Khosla Ventures, Uncork Capital, Alumni Ventures, Basecamp Fund, big_bets, Feld Ventures, Gaingels and 7 more.
- Where is Menten AI headquartered?
- Menten AI is headquartered in San Francisco, US.